United States Patent 5,804,570: Alendronate Non-Vertebral Fracture Claims, Patent Scope, and Generic Risk

United States Patent 5,804,570 covers a clinical method of using alendronate to reduce non-vertebral fracture risk in osteoporotic women, particularly postmenopausal and elderly women. Its narrower claims specify oral administration, daily doses of 2.5 mg, 5 mg, 10 mg, or 20 mg, and treatment extending beyond two or three years.

The patent is expired. It no longer creates a U.S. patent barrier to generic alendronate, and it does not support a current Paragraph IV enforcement strategy. Its principal historical value was as a method-of-use patent covering fracture-risk reduction rather than the alendronate molecule, tablet formulation, manufacturing process, or weekly dosing regimen.

What does U.S. Patent 5,804,570 protect?

The patent protects the use of alendronate, or a pharmaceutically acceptable salt such as alendronate sodium, in osteoporotic women to reduce the risk of non-vertebral fractures.

The broadest independent claim is claim 1:

A method of reducing the risk of non-vertebral fractures in an osteoporotic female comprising administering an effective amount of alendronate or a pharmaceutically acceptable salt thereof.

The claim has five principal limitations:

The patient is female.
The patient has osteoporosis.
The treatment uses alendronate or an acceptable salt.
The treatment administers an effective amount.
The objective is reducing the risk of non-vertebral fractures.

The claim does not expressly require:

Oral administration.
A particular dose.
Daily administration.
Postmenopausal status.
Elderly status.
A specified treatment duration.
A particular tablet, solution, excipient, coating, or crystalline form.
A diagnosis based on a particular bone-mineral-density threshold.

Those limitations appear in dependent claims or in the separate independent claim 8.

How do the claims differ from one another?

Claim group	Key limitations	Practical scope
Claim 1	Osteoporotic female; alendronate; reduce non-vertebral fractures	Broadest method claim
Claims 2-4	Oral use; 2.5-20 mg daily; specifically 10 mg daily	Oral daily treatment, including the historical Fosamax 10 mg regimen
Claims 5-6	Oral use; substantially daily; more than two years or at least about three years	Long-duration treatment
Claim 7	Claim 1 patient is elderly	Elderly osteoporotic women
Claim 8	Osteoporotic postmenopausal female; 2.5-20 mg; substantially daily; substantial period	Independent postmenopausal regimen claim
Claim 9	Claim 8 patient is elderly	Elderly postmenopausal women
Claim 10	Claim 1 treatment continues for a substantial period	Duration limitation
Claims 11-12	2.5 mg or 5 mg daily	Low-dose daily regimens
Claims 13-16	Claim 8 at 2.5, 5, 10, or 20 mg daily	Dose-specific postmenopausal regimens

Claims 1 and 8 are the principal commercial claims. Claims 2 through 7 and 9 through 16 narrow the patient population, dose, route, or duration.

What is the scope of the alendronate fracture-reduction claims?

Claim 1 is a treatment-purpose claim. It does not claim alendronate as a chemical compound. It claims the administration of alendronate for a specified clinical result.

A product can therefore fall within the claim even if its manufacturer does not describe the product as “Fosamax,” provided the product is alendronate or an acceptable salt and is administered to the claimed patient population for the claimed fracture-reduction purpose.

Non-vertebral fracture limitation

The patent does not cover fracture prevention generally. The stated endpoint is non-vertebral fractures. That category ordinarily includes fractures outside the spine, such as:

Hip fractures.
Wrist or forearm fractures.
Pelvic fractures.
Humeral fractures.
Other peripheral skeletal fractures.

A treatment directed solely to vertebral fracture reduction would not literally satisfy the non-vertebral-fracture limitation, although the same therapy could implicate the claim if it is also intended to reduce non-vertebral fracture risk.

Osteoporosis limitation

The patient must have osteoporosis. Treatment of osteopenia, ordinary age-related bone loss, or fracture risk without osteoporosis may fall outside the literal scope of claim 1, depending on the clinical diagnosis and evidence.

The patent does not state a single mandatory bone-mineral-density cutoff in the claims supplied. The issue would therefore turn on how “osteoporotic” is diagnosed and documented in the relevant treatment record.

Female and postmenopausal limitations

Claims 1 through 7 and 10 through 12 require a female patient. Claim 8 and its dependents require a postmenopausal female.

Treatment of an osteoporotic male is outside the literal scope of these claims. A postmenopausal limitation is not present in claim 1, so claim 1 is broader than claim 8 with respect to menopausal status.

Effective amount

“Effective amount” is functional language tied to the claimed result. The amount must be sufficient to reduce the risk of non-vertebral fractures in the treated patient.

This limitation can create proof issues. A claimant would generally need to show that the administered dose and treatment program were intended and capable of achieving the claimed clinical effect. The claim does not require that every individual patient avoid a fracture.

What doses and schedules are covered by Patent 5,804,570?

The patent covers daily oral doses from 2.5 mg to 20 mg under claims 3 and 8.

Dose	Expressly covered?	Relevant claims
2.5 mg daily	Yes	3, 11, 13
5 mg daily	Yes	3, 12, 14
10 mg daily	Yes	4, 15
20 mg daily	Yes	8, 16

The claims do not expressly cover once-weekly administration. A weekly regimen could potentially be analyzed under claim 1 if it satisfies the “effective amount” and fracture-risk limitations, but it would not meet claims requiring oral daily administration or a daily dose.

The patent is therefore distinct from later alendronate claims directed specifically to once-weekly dosing, including 35 mg and 70 mg weekly regimens.

What treatment duration is required?

Claims 5 and 6 require:

Substantially daily treatment for more than two years; or
Substantially daily treatment for at least about three years.

Claims 8 and 10 use the less precise terms “substantially daily” and “substantial period of time.”

These phrases create construction issues:

“Substantially daily” permits some missed doses but does not define a fixed adherence percentage.
“More than two years” is more definite than “substantial period.”
“At least about three years” includes some tolerance around the three-year period because of the word “about.”
Claim 10 does not independently define the length of a “substantial period.”

The duration limitations are important for infringement analysis. A short prescription or brief treatment course would be less likely to satisfy claims 5, 6, 8, or 10, but it could still implicate claim 1 if the other limitations are met.

Is Patent 5,804,570 a formulation or manufacturing patent?

No. The supplied claims do not protect a formulation or manufacturing process.

The patent does not claim:

A particular tablet composition.
A specific excipient system.
An enteric coating.
A controlled-release formulation.
An oral solution formulation.
A crystalline form of alendronate.
A process for making alendronate.
A method for improving gastrointestinal tolerability.
A specific packaging configuration.

The reference to a “pharmaceutically acceptable salt” expands the active-agent coverage to salts suitable for pharmaceutical use. It does not convert the patent into a salt-selection or solid-form patent.

Separate patents could protect alendronate compounds, salts, dosage forms, formulations, or dosing schedules. Those rights must be analyzed independently from Patent 5,804,570.

What is the Orange Book status of Patent 5,804,570?

Patent 5,804,570 was associated historically with Merck’s Fosamax alendronate products and method-of-use protection. The relevant products included alendronate dosage forms used for osteoporosis treatment, including daily-dose products.

The patent is now expired. FDA Orange Book listings do not extend patent rights after expiration. The patent’s historical listing could have required an ANDA applicant to address the patent through:

A Paragraph III certification, accepting a later launch after expiration; or
A Paragraph IV certification, asserting that the patent was invalid, unenforceable, or would not be infringed.

Because the patent has expired, it is no longer a live Orange Book barrier to approval or commercial entry. Current Orange Book analysis should distinguish this patent from any separately listed later-expiring patents covering weekly dosing, formulations, or other Fosamax indications. (U.S. Food and Drug Administration, 2025a).

When did U.S. Patent 5,804,570 lose exclusivity?

The patent issued on September 8, 1998. Its term ran for 20 years from the applicable nonprovisional filing date under the post-Uruguay Round patent-term regime. Public patent records identify the relevant priority and filing history as dating to 1994 and 1995, placing the ordinary term end in 2014. The patent is recorded as expired and has no current enforceable term. (U.S. Patent No. 5,804,570, 1998; 35 U.S.C. § 154).

The patent did not retain effective exclusivity through a current pediatric extension or an active patent-term extension. Any historical Hatch-Waxman exclusivity associated with Fosamax does not revive the patent today.

What Paragraph IV challenges affected alendronate?

Generic alendronate applicants challenged Merck’s Fosamax patent estate through ANDA litigation. The disputes involved multiple Merck patents, not only Patent 5,804,570.

The principal commercial effect was that generic alendronate entered the U.S. market before the expiration of every later-issued method or dosing patent. The relevant litigation record included challenges to alendronate compound, osteoporosis-treatment, and dosing patents. The Federal Circuit addressed Merck’s alendronate patent disputes in Merck & Co. v. Teva Pharmaceuticals USA, Inc., 395 F.3d 1364 (Fed. Cir. 2005).

For Patent 5,804,570, the current legal consequence is straightforward: an applicant no longer needs to defeat the patent to launch because the patent term has ended. A historical Paragraph IV certification has no continuing blocking effect after expiration.

What litigation status affects Patent 5,804,570 today?

No live U.S. infringement action based solely on Patent 5,804,570 can create an ongoing exclusionary period after expiration. A claim for past damages would still be subject to ordinary limitations, standing, proof, and statutory defenses, but the patent cannot support an injunction against current generic sales.

Any current alendronate dispute would more likely concern:

False patent-listing or regulatory conduct.
Product labeling.
Trade dress or trademark issues.
Formulation or manufacturing patents.
Other branded bisphosphonate products.
Antitrust or settlement conduct.
Patent rights outside the United States.

Patent 5,804,570 itself is not a current launch blocker.

Did settlement agreements delay generic alendronate entry?

Merck’s alendronate patent disputes produced ANDA litigation and commercial settlements involving generic applicants. Settlement terms in pharmaceutical cases can address launch dates, licenses, authorized generic supply, and patent challenges.

The existence of a historical settlement does not extend the statutory term of Patent 5,804,570. A private agreement may have affected the timing of a particular applicant’s launch, but it cannot recreate an expired patent right or prevent an unrelated generic applicant from relying on the patent’s expiration.

The patent record alone does not establish the full commercial terms of every historical Merck-alendronate settlement.

How strong was the patent estate for alendronate?

Patent 5,804,570 had moderate historical value as part of a layered estate, but its standalone scope was narrower than a compound patent.

Patent-right category	Covered by 5,804,570?	Historical strategic value
Alendronate molecule	No	None as a standalone right
Pharmaceutically acceptable alendronate salts	Yes, as part of the treatment method	Moderate
Osteoporosis treatment	Yes	Moderate
Non-vertebral fracture-risk reduction	Yes	High clinical specificity
Oral daily dosing	Yes	Moderate
10 mg daily regimen	Yes	Commercially relevant
2.5 mg, 5 mg, and 20 mg daily regimens	Yes	Narrower
Long-term treatment	Yes	Potentially useful but fact-intensive
Once-weekly dosing	Not expressly claimed	Limited
Tablet formulation	No	None
Manufacturing process	No	None
Product labeling	No direct claim	Indirect relevance only

The strongest feature was the connection between a named active ingredient and a defined clinical outcome. The principal weaknesses were the functional and potentially indefinite terms “effective amount,” “substantially daily,” and “substantial period of time,” together with the need to prove the patient diagnosis and intended fracture-reduction use.

How does Patent 5,804,570 compare with competing osteoporosis patent estates?

Patent 5,804,570 is narrower than an active-ingredient patent and broader than a formulation patent in clinical-use terms.

Estate type	Typical claim focus	Comparison with 5,804,570
Alendronate compound patent	Chemical structure or salt	More fundamental, but expires earlier
Daily osteoporosis method patent	Osteoporosis treatment and dose	Closely related
Non-vertebral fracture method patent	Specific clinical endpoint	Same category as 5,804,570
Weekly alendronate patent	35 mg or 70 mg weekly treatment	Different schedule
Formulation patent	Tablet, solution, excipients, coating	Product-specific and separate
Risedronate or ibandronate estate	Competing bisphosphonate products	No direct claim overlap in active ingredient
Denosumab estate	Biologic antiresorptive therapy	Separate biologic patent and regulatory pathway
Zoledronic acid estate	Intravenous bisphosphonate	Separate compound and administration profile

The patent does not create biosimilar risk because alendronate is a small-molecule drug. Competitors use the ANDA pathway for generic alendronate, not the abbreviated biosimilar pathway under the Public Health Service Act.

What generic launch risks remain for alendronate?

Patent 5,804,570 presents no current generic launch risk in the United States.

The historical risks included:

Induced infringement. A generic label or promotional material could have encouraged the claimed use.
Method-of-use labeling. A product label directed to osteoporotic postmenopausal women and non-vertebral fracture reduction could have supported an infringement theory.
Multiple-patent layering. An applicant could clear this patent while facing separate compound, formulation, or weekly-dosing patents.
Regulatory exclusivity. FDA exclusivity could delay approval independently of patent expiration.
Settlement restrictions. A private settlement could impose a contractual launch date earlier than the patent expiration date.

Those risks are historical for this patent. Current competitors face ordinary regulatory, manufacturing, quality, labeling, and commercial risks rather than a live exclusionary right under Patent 5,804,570.

What geographic coverage does Patent 5,804,570 provide?

The patent provides rights only in the United States. It does not establish protection in:

Canada.
Europe.
Japan.
China.
Australia.
Latin America.
Other jurisdictions.

Foreign counterparts may have had different claim scope, expiration dates, prosecution histories, and legal outcomes. A U.S. expiration does not establish worldwide freedom to operate, although the U.S. patent itself has no current force outside the United States or after expiration.

What is the commercial significance of the expired patent?

Fosamax was a major Merck osteoporosis product, and fracture-prevention claims supported premium branded positioning during the patent-protected period. Once generic alendronate became available, price competition materially reduced branded revenue.

Patent 5,804,570 did not protect all revenue from Fosamax. Its contribution was limited to the claimed use in osteoporotic women and the specified dosing and duration programs. Revenue associated with other indications, patient groups, formulations, or dosing schedules would require separate patent and labeling analysis.

The expiration of the patent removes a legal barrier but does not determine market share. Generic substitution, reimbursement policy, physician prescribing, patient adherence, product availability, and competing therapies such as denosumab, zoledronic acid, risedronate, and ibandronate determine the remaining commercial position.

Key Takeaways

U.S. Patent 5,804,570 is a method-of-use patent for reducing non-vertebral fracture risk with alendronate.
Claim 1 is the broadest claim and covers an osteoporotic female treated with an effective amount of alendronate or an acceptable salt.
Other claims narrow the scope to oral dosing, daily doses of 2.5 mg to 20 mg, postmenopausal or elderly women, and treatment lasting more than two or three years.
The patent does not claim the alendronate molecule, a tablet formulation, a manufacturing process, or a once-weekly regimen.
The patent is expired and does not present a current U.S. generic-entry barrier.
Generic alendronate uses the ANDA pathway; biosimilar analysis does not apply.
Any current freedom-to-operate review must examine separate alendronate formulation, dosing, labeling, and manufacturing rights.
The patent’s historical value came from its clinical endpoint and its role in Merck’s layered Fosamax patent estate.

FAQs About U.S. Patent 5,804,570

Can a generic alendronate company sell 10 mg daily tablets after Patent 5,804,570 expired?

Yes. The patent’s 10 mg daily claims no longer prevent U.S. sale because the patent term has ended, subject to separate regulatory and patent rights.

Does Patent 5,804,570 cover alendronate for men with osteoporosis?

No. The supplied claims require a female patient. They do not literally cover treatment of an osteoporotic male.

Does the patent cover alendronate for vertebral fracture prevention only?

No. The claims require reduction of non-vertebral fracture risk. A use limited to vertebral fractures does not satisfy that express limitation.

Could a weekly 70 mg alendronate regimen infringe Patent 5,804,570?

The claims expressly focus on daily administration for the narrower dose claims. A weekly regimen would require a separate analysis under the broadest claim and would more directly implicate distinct weekly-dosing patents.

Is Patent 5,804,570 relevant to denosumab or zoledronic acid?

No direct claim overlap exists because the patent requires alendronate or an acceptable alendronate salt. Denosumab and zoledronic acid have separate patent, regulatory, and product estates.

References

Food and Drug Administration. (2025a). Approved drug products with therapeutic equivalence evaluations: Orange Book. U.S. Department of Health and Human Services.
Merck & Co. v. Teva Pharmaceuticals USA, Inc., 395 F.3d 1364 (Fed. Cir. 2005).
United States Patent No. 5,804,570. (1998). Method for treating osteoporosis. U.S. Patent and Trademark Office.
35 U.S.C. § 154. (2025). Contents and term of patent; provisional rights.
U.S. Food and Drug Administration. (2025b). Approved drug label: Fosamax (alendronate sodium). U.S. Department of Health and Human Services.

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	002707	⤷ Start Trial
Australia	4922796	⤷ Start Trial
Australia	4979996	⤷ Start Trial
Australia	689379	⤷ Start Trial
Australia	690431	⤷ Start Trial
Canada	2212996	⤷ Start Trial
Canada	2213076	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 5,804,570

Summary for Patent: 5,804,570